parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.06 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in neutrophils	0.75
chemistry Open Targets	compounds already reach it: efalizumab, lifitegrast, odulimomab +1	1.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	Reactome did not answer (Reactome: The operation was aborted due to timeout)	0.00

No case: the score is under the bar. Receipt 4298

receipt 4306: ITGAL in dopamine neurons, braak

power: full sample -0.46 (p 0.057, n 18), 95% CI -0.76 to +0.01. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.45 (p 0.062, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.44 (p 0.064, n 18). could be the mix.
skeptic: leave-one-out range -0.60 to -0.38, sign flips 0; without severely affected donors -0.46 (p 0.057, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ITGAL in dopamine neurons.

case closed: nothing better to follow up.

receipt 4305: ITGAL in microglia, braak

power: full sample +0.03 (p 0.908, n 18), 95% CI -0.44 to +0.49. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.00 (p 0.990, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: +0.02 (p 0.928, n 18). could be the mix.
skeptic: leave-one-out range -0.12 to +0.13, sign flips 6; without severely affected donors +0.03 (p 0.908, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ITGAL in microglia.

case closed: nothing better to follow up.

loading the receipts